BCY LifeSciences Provides DCF 987 Cystic Fibrosis Phase II Clinical

[Guest guest]

                               Canada NewsWire

                           February 11, 2003, Tuesday

HEADLINE: BCY LifeSciences Provides DCF 987 Cystic Fibrosis Phase II

Clinical

Trial Update;

  BCY LIFESCIENCES INC. (TSXV: BCY)

DATELINE: TORONTO, Feb. 11

   Because of numerous calls from the investment

community seeking information on the status of BCY's Phase II Clinical

Trial

in cystic fibrosis (CF), BCY LifeSciences Inc. (TSXV: BCY) today is

pleased to

provide the following update.

    The first patient was entered into the trial on January 7, 2003. The

patient has now completed 28 days of therapy without any reports to the

Company of complications. In the time since January 7, 21 patients have

entered the Phase II trial. Some of these patients are now nearing

completion

of their treatment. In total, the Company plans to enroll 75 patients in

the

Phase II clinical trial for DCF 987. DCF 987 is the low molecular weight

dextran BCY has under development for the treatment of respiratory

disorders

which include cystic fibrosis. The compound is an aerosol formulation and

is

administered by using equipment already in use by the CF patient to

deliver

other medication needs. All of the patients in this phase of the trial

are

sixteen years of age or older. Younger patients are planned to be

included in

future studies which will follow successful completion of the Phase II

clinical trial.

    " We are pleased that all six centers have patients in the trial and

are

in the process of adding more CF patients " , stated Lorne Meikle,

President &

CEO of the Company. " The holiday season initially slowed the start of the

study, but enrollment is now on plan and if it continues at the present

rate,

the trial could be finished mid year 2003. "

     The Company plans to provide periodic updates to the medical and

investment communities as the trial progresses.

       About BCY LifeSciences

    BCY LifeSciences is pharmaceutical development company dedicated to

acquiring and developing innovative pharmaceutical products or

technologies

that serve unmet medical needs with an initial focus on technologies

targeting

cystic fibrosis (CF). This press release, as well as other press releases

and

corporate information, can be found on the Company web site:

www.BCYLifesciences.com.

       This news release contains projections and other forward-looking

statements regarding future events. Such statements are predictions,

which may

involve known and unknown risks, uncertainties and other factors, which

could

cause the actual events or results and company plans and objectives to

differ

materially from those expressed. For information concerning factors

affecting

the company's business, the reader is referred to the documents that the

company files from time to time with applicable Canadian securities and

regulatory authorities.

       The TSX Venture Exchange has not reviewed and does not accept

responsibility for the adequacy or accuracy of this release.

   VIEW ADDITIONAL COMPANY-SPECIFIC INFORMATION:

http://www.newswire.ca/cgi-bin/inquiry.cgi?OKEY=19050

CONTACT: contact - Lorne Meikle, President and CEO, BCY LifeSciences

Inc., (416)

484.4666 x 225

Becki

YOUR FAVORITE LilGooberGirl

YOUNGLUNG EMAIL SUPPORT LIST

www.topica.com/lists/younglung

Pediatric Interstitial Lung Disease Society

http://groups.yahoo.com/group/InterstitialLung_Kids/